Literature DB >> 28723508

Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team.

Rahul Aggarwal1, Tomasz M Beer2, Martin Gleave3, Joshua M Stuart4, Matthew Rettig5, Christopher P Evans6, Jack Youngren7, Joshi J Alumkal2, Jiaoti Huang8, George Thomas2, Owen Witte6, Eric J Small7.   

Abstract

The Stand Up 2 Cancer/Prostate Cancer Foundation-funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases. Accrual is expected to be complete by December 2016.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (AR) pathway inhibitors; abiraterone; enzalutamide

Year:  2016        PMID： 28723508     DOI： 10.1016/j.euf.2016.10.011

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  7 in total

1.  Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.

Authors:  Rahul R Aggarwal; David A Quigley; Jiaoti Huang; Li Zhang; Tomasz M Beer; Matthew B Rettig; Rob E Reiter; Martin E Gleave; George V Thomas; Adam Foye; Denise Playdle; Paul Lloyd; Kim N Chi; Christopher P Evans; Primo N Lara; Felix Y Feng; Joshi J Alumkal; Eric J Small
Journal:  Mol Cancer Res       Date:  2019-03-27       Impact factor: 5.852

2.  Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Authors:  Yang Su; Yue Liu; Christopher R Behrens; Scott Bidlingmaier; Nam-Kyung Lee; Rahul Aggarwal; Daniel W Sherbenou; Alma L Burlingame; Byron C Hann; Jeffry P Simko; Gayatri Premasekharan; Pamela L Paris; Marc A Shuman; Youngho Seo; Eric J Small; Bin Liu
Journal:  JCI Insight       Date:  2018-09-06

3.  Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.

Authors:  John K Lee; Nathanael J Bangayan; Timothy Chai; Bryan A Smith; Tiffany E Pariva; Sangwon Yun; Ajay Vashisht; Qingfu Zhang; Jung Wook Park; Eva Corey; Jiaoti Huang; Thomas G Graeber; James Wohlschlegel; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

4.  Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy.

Authors:  Hao Geng; Changhui Xue; Janet Mendonca; Xiao-Xin Sun; Qiong Liu; Patrick N Reardon; Yingxiao Chen; Kendrick Qian; Vivian Hua; Alice Chen; Freddy Pan; Julia Yuan; Sang Dang; Tomasz M Beer; Mu-Shui Dai; Sushant K Kachhap; David Z Qian
Journal:  Nat Commun       Date:  2018-11-26       Impact factor: 14.919

5.  The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.

Authors:  Neha Singh; Varune R Ramnarine; Jin H Song; Ritu Pandey; Sathish K R Padi; Mannan Nouri; Virginie Olive; Maxim Kobelev; Koichi Okumura; David McCarthy; Michelle M Hanna; Piali Mukherjee; Belinda Sun; Benjamin R Lee; J Brandon Parker; Debabrata Chakravarti; Noel A Warfel; Muhan Zhou; Jeremiah J Bearss; Ewan A Gibb; Mohammed Alshalalfa; R Jefferey Karnes; Eric J Small; Rahul Aggarwal; Felix Feng; Yuzhuo Wang; Ralph Buttyan; Amina Zoubeidi; Mark Rubin; Martin Gleave; Frank J Slack; Elai Davicioni; Himisha Beltran; Colin Collins; Andrew S Kraft
Journal:  Nat Commun       Date:  2021-12-21       Impact factor: 17.694

6.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Authors:  David A Quigley; Ha X Dang; Shuang G Zhao; Paul Lloyd; Rahul Aggarwal; Joshi J Alumkal; Adam Foye; Vishal Kothari; Marc D Perry; Adina M Bailey; Denise Playdle; Travis J Barnard; Li Zhang; Jin Zhang; Jack F Youngren; Marcin P Cieslik; Abhijit Parolia; Tomasz M Beer; George Thomas; Kim N Chi; Martin Gleave; Nathan A Lack; Amina Zoubeidi; Robert E Reiter; Matthew B Rettig; Owen Witte; Charles J Ryan; Lawrence Fong; Won Kim; Terence Friedlander; Jonathan Chou; Haolong Li; Rajdeep Das; Hui Li; Ruhollah Moussavi-Baygi; Hani Goodarzi; Luke A Gilbert; Primo N Lara; Christopher P Evans; Theodore C Goldstein; Joshua M Stuart; Scott A Tomlins; Daniel E Spratt; R Keira Cheetham; Donavan T Cheng; Kyle Farh; Julian S Gehring; Jörg Hakenberg; Arnold Liao; Philip G Febbo; John Shon; Brad Sickler; Serafim Batzoglou; Karen E Knudsen; Housheng H He; Jiaoti Huang; Alexander W Wyatt; Scott M Dehm; Alan Ashworth; Arul M Chinnaiyan; Christopher A Maher; Eric J Small; Felix Y Feng
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

7.  Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

Authors:  Alexander W Wyatt; Matti Annala; Rahul Aggarwal; Kevin Beja; Felix Feng; Jack Youngren; Adam Foye; Paul Lloyd; Matti Nykter; Tomasz M Beer; Joshi J Alumkal; George V Thomas; Robert E Reiter; Matthew B Rettig; Christopher P Evans; Allen C Gao; Kim N Chi; Eric J Small; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2017-12-01       Impact factor: 13.506
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.